Summaries for patients. Antiviral regimens for chronic hepatitis B virus infection.
D000225:Adenine / Q000031:analogs & derivatives* / Q000191:economics / Q000627:therapeutic use; D000998:Antiviral Agents / Q000191:economics* / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D003661:Decision Support Techniques; D006513:Hepatitis B e Antigens / Q000097:blood; D006515:Hepatitis B virus / Q000276:immunology; D019694:Hepatitis B, Chronic / Q000188:drug therapy* / Q000201:enzymology / Q000821:virology; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000191:economics / Q000627:therapeutic use; D019259:Lamivudine / Q000191:economics / Q000627:therapeutic use; D008099:Liver / Q000201:enzymology; D008390:Markov Chains; D063065:Organophosphonates / Q000191:economics / Q000627:therapeutic use; D011994:Recombinant Proteins; D016879:Salvage Therapy; D012680:Sensitivity and Specificity; D000637:Transaminases / Q000097:blood
D000998:Antiviral Agents; D006513:Hepatitis B e Antigens; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D063065:Organophosphonates; D011994:Recombinant Proteins; D019259:Lamivudine; C053001:adefovir; D000637:Transaminases; D000225:Adenine